Felix Lötsch, Lukas Bouvier-Azula, Wolfgang Barousch, Iris Camp, Peter Starzengruber, Athanasios Makristathis, Birgit Willinger
{"title":"Clinical Utility of the T2Candida Panel: A Real-World Analysis of More Than 2000 Cases.","authors":"Felix Lötsch, Lukas Bouvier-Azula, Wolfgang Barousch, Iris Camp, Peter Starzengruber, Athanasios Makristathis, Birgit Willinger","doi":"10.1007/s11046-025-00979-x","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Invasive candidiasis, including candidaemia, is associated with high morbidity and mortality. Diagnosis is traditionally based on blood culture, which lacks sensitivity. Therefore, additional tools such as PCR-based diagnostic methods are increasingly used. The T2MR technology is based on polymerase chain reaction and detection of the PCR product involving magnetic resonance technology. In this study, we compare the T2Candida in a clinical routine setting to conventional blood culture in order to explore its usefulness, strengths and weaknesses in its daily application.</p><p><strong>Methods: </strong>This retrospective analysis was performed at the Vienna University Hospital with clinical routine samples submitted between April 2021 and May 2024. Sensitivity, specificity, positive predictive value, negative predictive value and accordance were calculated with blood culture as reference method. Patients with a positive T2Candida result but a negative result in blood culture were assessed according to a clinical case definition. Based on direct detection in blood by alternative methods (e.g. blood culture, alternative PCR), 1-3-beta-D-Glucan, patient risk factors and detection of the same species in other sample materials, each result was categorised as \"proven\", \"probable\", \"possible\", \"improbable\" or \"not assessable\".</p><p><strong>Results: </strong>2105 samples from 1447 unique patients were submitted for analysis during the study period. 94 samples were positive (4.5%) in the T2Candida, with 4 samples positive for more than one target. 26 out of these 94 (27.7%) were also positive in blood culture. 339 (16.1%) samples were invalid. The most frequent species detected was Candida albicans/tropicalis with 57 detections. Overall sensitivity of the T2Candida panel in our setting was 0.62 (95% CI 0.41-0.80) and specificity was 0.96 (95% CI 0.95-0.97). Cases detected by the T2Candida panel were assessed as proven (n = 28), probable (n = 11), possible (n = 29), improbable (n = 15) and not assessable (n = 15). Median time-to-result was 3.9 h for the T2Candida compared to a median time-to-positivity of blood culture ranging from 22.7 to 42.0 h depending on the species.</p><p><strong>Conclusions: </strong>The introduction of the T2Candida panel led to a substantial rise in patients diagnosed with invasive candidiasis. Combination of both the T2Candida panel and conventional blood culture led to the detection of more positive samples than each test alone.</p>","PeriodicalId":19017,"journal":{"name":"Mycopathologia","volume":"190 5","pages":"71"},"PeriodicalIF":2.9000,"publicationDate":"2025-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12343663/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Mycopathologia","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1007/s11046-025-00979-x","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MYCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Objectives: Invasive candidiasis, including candidaemia, is associated with high morbidity and mortality. Diagnosis is traditionally based on blood culture, which lacks sensitivity. Therefore, additional tools such as PCR-based diagnostic methods are increasingly used. The T2MR technology is based on polymerase chain reaction and detection of the PCR product involving magnetic resonance technology. In this study, we compare the T2Candida in a clinical routine setting to conventional blood culture in order to explore its usefulness, strengths and weaknesses in its daily application.
Methods: This retrospective analysis was performed at the Vienna University Hospital with clinical routine samples submitted between April 2021 and May 2024. Sensitivity, specificity, positive predictive value, negative predictive value and accordance were calculated with blood culture as reference method. Patients with a positive T2Candida result but a negative result in blood culture were assessed according to a clinical case definition. Based on direct detection in blood by alternative methods (e.g. blood culture, alternative PCR), 1-3-beta-D-Glucan, patient risk factors and detection of the same species in other sample materials, each result was categorised as "proven", "probable", "possible", "improbable" or "not assessable".
Results: 2105 samples from 1447 unique patients were submitted for analysis during the study period. 94 samples were positive (4.5%) in the T2Candida, with 4 samples positive for more than one target. 26 out of these 94 (27.7%) were also positive in blood culture. 339 (16.1%) samples were invalid. The most frequent species detected was Candida albicans/tropicalis with 57 detections. Overall sensitivity of the T2Candida panel in our setting was 0.62 (95% CI 0.41-0.80) and specificity was 0.96 (95% CI 0.95-0.97). Cases detected by the T2Candida panel were assessed as proven (n = 28), probable (n = 11), possible (n = 29), improbable (n = 15) and not assessable (n = 15). Median time-to-result was 3.9 h for the T2Candida compared to a median time-to-positivity of blood culture ranging from 22.7 to 42.0 h depending on the species.
Conclusions: The introduction of the T2Candida panel led to a substantial rise in patients diagnosed with invasive candidiasis. Combination of both the T2Candida panel and conventional blood culture led to the detection of more positive samples than each test alone.
期刊介绍:
Mycopathologia is an official journal of the International Union of Microbiological Societies (IUMS). Mycopathologia was founded in 1938 with the mission to ‘diffuse the understanding of fungal diseases in man and animals among mycologists’. Many of the milestones discoveries in the field of medical mycology have been communicated through the pages of this journal. Mycopathologia covers a diverse, interdisciplinary range of topics that is unique in breadth and depth. The journal publishes peer-reviewed, original articles highlighting important developments concerning medically important fungi and fungal diseases. The journal highlights important developments in fungal systematics and taxonomy, laboratory diagnosis of fungal infections, antifungal drugs, clinical presentation and treatment, and epidemiology of fungal diseases globally. Timely opinion articles, mini-reviews, and other communications are usually invited at the discretion of the editorial board. Unique case reports highlighting unprecedented progress in the diagnosis and treatment of fungal infections, are published in every issue of the journal. MycopathologiaIMAGE is another regular feature for a brief clinical report of potential interest to a mixed audience of physicians and laboratory scientists. MycopathologiaGENOME is designed for the rapid publication of new genomes of human and animal pathogenic fungi using a checklist-based, standardized format.